Oncolytics Biotech Inc.

Introduction:

Operation: Cutting-Edge Research and Development in Oncolytic Virotherapy

At the forefront of the battle against cancer, Oncolytics Biotech Inc. operates on the cutting edge of oncolytic virotherapy research and development. The company's operations revolve around harnessing the power of viruses to selectively target and destroy cancer cells while sparing healthy tissues. Through a meticulous approach, Oncolytics Biotech's team of scientists, physicians, and industry experts works tirelessly to develop innovative oncolytic viruses that exploit the vulnerabilities of cancer cells.

Mission: Transforming Lives by Redefining Cancer Treatment

Oncolytics Biotech Inc. is driven by a powerful mission: to transform the lives of cancer patients by redefining the way cancer is treated. With a deep commitment to advancing oncolytic virotherapy, the company aims to provide more effective and personalized treatment options that maximize therapeutic outcomes. By leveraging the body's own immune system and developing targeted therapies, Oncolytics Biotech seeks to revolutionize the field of oncology and improve patient outcomes worldwide.

Please note that the above paragraphs are generated based on the information available on the official website of Oncolytics Biotech Inc. as of my knowledge cutoff in September 2021. For the most up-to-date and accurate information, please refer to the company's official communications and documents.

Executive Team and Board of Directors:

Founders of Oncolytics Biotech.:

Matt Coffey is the founder of Oncolytics and completed his PhD at the University of Calgary in oncology, specifically focusing on reoviruses. Matt Coffey published many successful research papers before he cofounded Oncoltyics Biotech. Within the company, Coffey excelled in various roles including Chief executive officer, Chief operating officer, Chief scientific officer and Vice President of Product development and Chief financial officer.

Management Team:

Matt Coffey, PhD, MBA is the Chief Executive Officer of Oncolytics and completed his PhD at the University of Calgary in oncology, specifically focusing on reoviruses. Matt Coffey published many successful research papers before he cofounded Oncoltyics Biotech. Within the company, Coffey excelled in various roles including Chief executive officer, Chief operating officer, Chief scientific officer and Vice President of Product development and Chief financial officer.

Kirk Look is the Chief Financial Officer of Oncolytics and is a highly experienced chartered accountant. Before joining the company in 2003 Look was the manager of Audit and Assurance services in the prestigious accounting firm Ernst & Young in Canada.

Thomas C. Heineman, MD, PhD is the Chief Medical Officer of Oncolytics. He completed his PhD at the University of Chigaco in Virology.  Prior to his position in Oncolytics Dr Heineman worked in various roles which were Head of clinical development at Denovo, Vice President, Head of Clinical Development at both Genocea Biosciences and Halozyme Therapeutics, Senior Director of Global Clinical Research and Development at GlaxoSmithKline and as an Associate Professor at the Saint Louis University School of Medicine.

Allison Hagerman is the Vice President of Product Development at Oncolytics. Ms. Hagerman is a biotechnology professional engineer and has been Director of Manufacturing and Engineering and Project Manager in Oncolytics. During this time she led the team to for the performance qualification of Pelareorep drug substance.

Andrew de Guttadauro is the President and Global Head of Business Development at Oncolytics Biotech. Mr. Guttadauro has held executive and senior-level positions at leading pharmaceutical and biotechnology companies.

Board of Directors:

Matt Coffey, PhD, MBA is a Director in Oncolytics and completed his PhD at the University of Calgary in oncology, specifically focusing on reoviruses. Matt Coffey published many successful research papers before he cofounded Oncoltyics Biotech. Within the company, Coffey excelled in various roles including Chief executive officer, Chief operating officer, Chief scientific officer and Vice President of Product development and Chief financial officer.

Wayne Pisano is a Director at Oncolytics and has had a very successful career and been recognized in 2010 as Pharma Executive of the Year by the World Vaccine Congress. He has served a plethora of roles including: President and CEO of VaxInnate (a privately held biotech company), member of Immunovaccine's Board in October 2011 and lastly he was the former President and CEO of Sanofi Pasteur (one of the largest vaccine companies in the world).

Jonathan Rigby is a Director at Oncolytics. He is currently the Group Chief Executive Officer of Revolo Biotherapeutics, where he is focused on the development of therapies for autoimmune and allergic diseases. Other than this he has lots of experience in the biotech industry including CEO of SteadyMed Ltd, Co-founding Zogenix, Inc. (a CNS-focused specialty pharmaceutical company), being a member of the Revolo Biotherapeutics and ImmunoMolecular Therapeutics Boards of Directors and lastly the Chairman of BIOS (a Nasdaq-listed biotech acquisition company).

Deborah M. Brown, MBA is a Director at Oncolytics. Ms. Brown has many achievements including being a current Managing Partner at Accelera (a specialty consultancy firm that assists emerging biopharma ventures in the United States and Europe) Canada. She has previously been Executive Vice President of Neuroimmunology and President and Managing Director of the company's Canadian operations at EMD Serono. Ms. Brown has also been Chair of the National Pharmaceutical Organization (now Innovative Medicines Canada), Life Sciences Ontario, the Strategic Executive Advisory Council for Canadian Cancer Trials Group, and her local SPCA.

Bernd R. Seizinger, MD, PhD is a Director at Oncolytics. Dr. Bernd., currently serves as board member in numerous public and private biotech companies including: Vaccibody, Oxford BioTherapeutics, Aprea, CryptoMedix, and BioInvent. In previous roles he was simultaneously President & CEO of GPC Biotech (VP Oncology Drug Discovery) while also serving as VP Corporate and Academic Alliances at Bristol-Myers Squibb, and as Executive VP and CSO of Genome Therapeutics. Prior to his corporate appointments, he held Senior Faculty positions at Harvard Medical School, Massachusetts General Hospital and Princeton University.

James T. Parsons is a Director at Oncolytics. His executive experience includes, currently, being Chief Financial Officer of Trillium Therapeutics Inc. Previosuly he has been president of Empar Management, Vice President of Finance at DiaMedica Therapeutics Inc, CFO of ProMIS Neurosciences (formerly Amorfix Life Sciences Ltd.), and CFO and Vice President of Finance and Administration at Aptose Biosciences Inc. (formerly Lorus Therapeutics). Mr. Parsons has also been a Director and the Chair of the Audit Committees of Sernova Corp. and DiaMedica Therapeutics Inc.

Angela Holtham, MBA, is a Director at Oncolytics. She is currently the Senior Vice President and Chief Financial Officer of Canadian subsidiary of Nabisco Inc. She has also been the Vice President, Finance and Chief Financial Officer in the Ontario-based Hospital for Sick Children.

Risks

As with any investment, investing in Oncolytics Biotech carries a level of risk. Overall, based on the key risks highlighted below, the degree of risk associated with an investment in Oncolytics Biotech is very high.

Risks Related to the Companies Operations

• As a clinical stage pharmaceutical company, the prospects of Oncolytics Biotech is regarded as speculative, it is impossible to predict whether new therapeutics will ultimately prove to be safe and effective in humans or whether necessary and sufficient data can be developed through the clinical trial process to support a successful product application and approval
• Their current product in development, Pelareorep, is in it's R&D stage for human application, the riskiest stage for a company in the biotechnology industry
• If they are unable to establish that Pelareorep is a safe, effective treatment for cancer, they may be required to abandon further development of the product and develop a new business strategy

Risks related to the ability to grow the business

• If a product is approved for sale, product manufacturing at a commercial scale, and significant sales to end users at a commercially reasonable price may not be successful

• There can be no assurance that adequate funds will be generated to continue development or will ever achieve significant revenues or profitable operations

Risks related to government laws and regulations

• Human clinical trials must demonstrate that the product is safe for human use and that the product shows efficacy in order to obtain regulatory approvals for products being developed for human use, and to achieve commercial success

• In developing a pharmaceutical product, there is a reliance on employees, contractors, consultants and collaborators, and other third-party relationships, including the ability to obtain appropriate product liability insurance. There can be no assurance that this reliance and these relationships will continue as required

Risks related to the ownership of the company's common stock

• Market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress made

Relative Valuation

A comparable company analysis is undertaken using key metrics of Price-to-Book Ratio and EV/R&D Ratio, involving other companies operating in the biopharmaceutical sector, particularly those focusing on the development of oncology treatments.

Note that Oncolytics anticipates profitability only upon commercial viability of Pelareorep, which renders usual comparing metrics like P/E ratio unavailable.

	Market Data ($K)					Financial Data ($K)								Valuation (x)
Company	Ticker	Price	Shares Out	Market Cap	TEV	Revenue	EBITDA	EBIT	Net Income	Assets	Liabilities	Book Value	R&D Exp.	P/B	EV/R&D
Oncolytics Biotech Inc.	TSX:ONC	$2.78	65701	178090	156580	0	-20628	-20699	-19093	27585	8003	19582	11864	9.09x	13.20x
TME Pharma	PAR:ALTME	$1.6	5300	8662	8074	0	12551	12028	15910	5620	6327	-707		-12,25x

Summary

Oncolytics Biotech is a Canadian development-stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for cancer treatment, specifically with the aim of weakening tumour defence mechanisms. Oncolytics Biotech aims to use immunotherapeutics - a branch of biological therapies that use synthetic substances to activate the immune system for stronger responses. This approach proposes many new treatments (most of which are currently being tested in phase II clinical trials) that will support the immune system in a more powerful fight against cancer. Oncolytics Biotech represents a new type of medicine known as precision medicine. The company's lead product is Pelareorep, simply put, Pelareorep is an oncolytic virus that causes tumour cells to burst and activates multiple immune system entities.

Oncolytics Biotech has also decided to embark on a co-developmental journey with Merck KGaA and Pfizer to combine Pelareorep with Paclitaxel, a chemotherapy medication, and Avelumab, an anti-cancer antibody medication. This combination is being tested because oncolytic viruses, such as Pelareorep, have the potential to enhance existing cancer treatments like Paclitaxel and Avelumab, leading to the elimination of resistant cancer cells and reducing cancer relapses. Oncolytics Biotech is conducting experiments on breast cancer cells using Pelareorep and Pfizer's drug Bavencio (Avelumab).